• Most Popular
  • Most Shared

Caraco Pharmaceutical gets FDA nod to market generic Adipex-P

Wed Aug 22, 2007 12:59pm EDT

Stocks

   

Regulatory News

Aug 22 (Reuters) - Caraco Pharmaceutical Laboratories Ltd (CPD.A) said U.S. health regulators granted final approval for its generic version of Teva Pharmaceutical USA Inc's Adipex-P, which treats obesity. Phentermine HCl generic and brand products had combined annual sales of about $34 million for the twelve months ended June 2007, Caraco said, citing data tracking company IMS Health.

Teva Pharmaceutical USA Inc. is a unit of Teva Pharmaceutical Industries Ltd (TEVA.O).

(Reporting by Neha Pathania in Bangalore)

((Editing by Himani Sarkar; Reuters Messaging: neha.pathania.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: CARACO APPROVAL/ FDA

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2663



More from Reuters

Sturdy U.S. home sales bolster economic growth prospects

WASHINGTON (Reuters) - Sales of previously owned U.S. homes jumped last month to their highest level in nearly three years, the latest sign that the economic recovery was gaining steam, after growing below expectations in the third quarter.

Guadalupe Hernandez receives an ultrasound by nurse practitioner Gail Brown during a prenatal exam at the Maternity Outreach Mobile in Phoenix, Arizona October 8, 2009. Credit: REUTERS/Joshua Lott

Health reform inches closer

Democrats are on the verge of passing landmark legislation by Christmas, with only one more hurdle remaining.  Full Article | Video 

Photo

The end of the carry trade?

Borrowing the dollar cheaply to fund purchases of higher-yielding assets was a no-brainer in 2009, but will it be a safe bet in 2010?  Full Article